ABSTRACT
PURPOSE:
PRRT is a known tool in the management of patients with disseminated and inoperable NETs. The aim of study was to assess the effectiveness of the repeated cycles of PRRT in patients with disseminated and inoperable NETs.
MATERIAL AND METHODS:
Eighty nine patients were included in the PRRT. Among them 16 patients (18%) were qualified for a repeated PRRT cycle due to progression of the disease. In one of the patients qualified for the repeated cycle, PRRT was used as neoadjuvant therapy. The results and side-effects of the repeated cycles of PRRT were analyzed.
RESULTS:
Disease stabilization was observed in 10 patients 6 months after the repeated PRRT cycle and in 5 patients after 12 and 18 months. Ten of the patients who had received repeated PRRT cycles died. In the case of neoadjuvant therapy, further reduction of the tumor size was observed, enabling qualification for surgery. Clinically significant reduction in the mean values of morphological parameters was not observed. Only after 12 and 18 months the mean values of creatinine levels were higher than the normal range (only in 2 patients).
CONCLUSIONS:
The repeated cycles of PRRT did not cause a clinically significant increase of the toxicity of PRRT. The changes in kidney and blood morphology parameters were transient. The repeated cycles of PRRT enabled stabilization of the disease.
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET
Riferimento:
Radiother Oncol. 2012 Jan;102(1):45-50.
Autori:
Pach D, Sowa-Staszczak A, Kunikowska J, Królicki L, Trofimiuk M, Stefańska A, Tomaszuk M, Głowa B, Mikołajczak R,Pawlak D, Jabrocka-Hybel A, Hubalewska-Dydejczyk AB.
Fonte:
Radiother Oncol. 2012 Jan;102(1):45-50.
Anno:
2012
Azione:
La terapia del radionuclide peptide recettore (PRRT) con analoghi radiomarcati della somatostatina gioca un ruolo sempre più importante nel trattamento di pazienti con tumori neuroendocrini diffusi e inoperabili (NET).
Target:
Analoghi radiomarcati somatostatina/tumori neuroendocrini diffusi e inoperabili.
Sostanze: